Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Sunho Biologics's quick ratio for the quarter that ended in Jun. 2025 was 6.57.
Sunho Biologics has a quick ratio of 6.57. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sunho Biologics's Quick Ratio or its related term are showing as below:
HKSE:02898'
s Quick Ratio Range Over the Past 10 Years
Min: 0.21 Med: 6.57 Max: 14.77
Current: 6.57
During the past 3 years, Sunho Biologics's highest Quick Ratio was 14.77. The lowest was 0.21. And the median was 6.57.
HKSE:02898's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.565
vs HKSE:02898: 6.57
Sunho Biologics (HKSE:02898) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sunho Biologics Quick Ratio Related Terms
Sunho Biologics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Sunho Biologics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02898 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Sunho Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunho Biologics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunho Biologics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sunho Biologics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sunho Biologics's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunho Biologics (HKSE:02898) has a Quick Ratio of 6.57 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sunho Biologics and its competitors. This is near median its historical median of 6.57. Over the past decade, Sunho Biologics' Quick Ratio has ranged from 0.21 to 14.77.
Is Sunho Biologics' Quick Ratio too high?
Sunho Biologics' current Quick Ratio of 6.57 is near median its 10-year median of 6.57. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 14.77. The Biotechnology industry median Quick Ratio is 3.57. Sunho Biologics' value of 6.57 is 84.3% above this industry median. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' Quick Ratio compare to VRTX and REGN?
Sunho Biologics' Quick Ratio of 6.57 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.57. Sunho Biologics' value of 6.57 is 84.3% above this benchmark. Historically, Sunho Biologics' own Quick Ratio has ranged from 0.21 to 14.77 over the past decade. While the company's 10-year median is 6.57 vs. the industry median of 3.57, Sunho Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,406 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunho Biologics's current Quick Ratio of 6.57 is 84.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sunho Biologics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunho Biologics's current Quick Ratio is 6.57, which is near median its own 10-year median of 6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current Quick Ratio of 6.57. The current Quick Ratio is 6.57, which is near median its 10-year median of 6.57 and 84.3% above the Biotechnology industry median of 3.57. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current Quick Ratio is 6.57 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score
Get the complete analysis for HKSE:02898
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02898 has been successfully added to your 
